Reform of federal drug discount program should target misaligned incentives, researchers say

The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup